Dihui Cai

Abstract The safety of multi-dose mesenchymal stem cell (MSC) regimens has seldom been systematically investigated. The PRIME-HFrEF (Prospective Randomized Controlled Study of Multiple Intravenous Infusions of Umbilical Cord–derived MSCs in Patients with Heart Failure and Reduced Ejection Fraction) trial was a single-center, randomized, placebo-controlled, investigator-initiated study (ClinicalTrials.gov identifier: NCT04992832) that enrolled 40 patients.

Introduction Calcific aortic valve stenosis (CAVS) is the most common and severe valvular heart disease in high-income countries and a major public health burden.1 The prevalence of CAVS ranges from 10% to 15% in individuals over 75 years with projections indicating a likelihood of more than doubling by the year 2040.2 Many individuals diagnosed with CAVS not only experience dysfunction of the aortic valve but also frequently present with concurrent cardiovascular diseases (CVDs).3, 4...

Record: found Abstract: found Article: found Author(s): , , Publication date (Electronic): Keywords: , , , ScienceOpenPublisherPubMed There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience. Introduction: Recent studies have indicated that obstructive sleep apnea (OSA) is linked to a higher likelihood of heart failure (HF).